Tag Archives: ADVANCE

PLEGRIDY? (PEGINTERFERON BETA-1A) TWO-YEAR DATA CONFIRM MAINTENANCE OF EFFICACY AND SAFETY IN MULTIPLE SCLEROSIS PATIENTS

PLEGRIDY? (PEGINTERFERON BETA-1A) TWO-YEAR DATA CONFIRM MAINTENANCE OF EFFICACY AND SAFETY IN MULTIPLE SCLEROSIS PATIENTS

CAMBRIDGE, Mass. ? Sept. 11, 2014 ? Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY? (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study.…

CHMP ADOPTS POSITIVE OPINION FOR PLEGRIDYTM (PEGINTERFERON BETA-1A) AS A TREATMENT FOR MULTIPLE SCLEROSIS IN THE EUROPEAN UNION

? CAMBRIDGE, Mass. ? May 23, 2014 ? Biogen Idec (NASDAQ: BIIB) today received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization of PLEGRIDYTM (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS).…

BIOGEN IDEC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF PEGINTERFERON BETA-1A IN MULTIPLE SCLEROSIS

Weston, Mass. ? Jan. 24, 2013 ? Today Biogen Idec (NASDAQ: BIIB) released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE. Results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis (RRMS).…
Top